Article Text

PDF
Ursodeoxycholic acid improves muscle contractility and inflammation in symptomatic gallbladders with cholesterol gallstones
  1. Michele Pier Luca Guarino1,
  2. Ping Cong2,
  3. Michele Cicala1,
  4. Rossana Alloni1,
  5. Simone Carotti1,
  6. Jose Behar2
  1. 1Department of Digestive Disease, Campus Bio Medico University of Rome, Rome, Italy
  2. 2Rhode Island Hospital and Brown University Medical School, Providence, Rhode Island, USA
  1. Correspondence to:
    Dr M P Luca Guarino
    Dipartimento di Malattie dell’Apparato Digerente, Università Campus Bio-Medico, Via Longoni, 83 - 00155 Rome, Italy;m.guarino{at}unicampus.it

Abstract

Objective: To examine the mechanisms of action of ursodeoxycholic acid (UDCA) on gallbladder (GB) muscle cells in patients with symptomatic cholesterol gallstones (GSs) as it reduces the incidence of acute cholecystitis.

Design and patients: A double-blind study was performed on 15 patients, 7 randomised to UDCA and 8 to placebo, treated for 4 weeks before cholecystectomy. Muscle contraction induced by cholecystokinin (CCK)-8, acetylcholine (ACh) and potassium chloride (KCl) was determined in enzymatically isolated GB muscle cells, and cholesterol levels were determined in plasma membranes. H2O2, lipid peroxidation, platelet-activating factor (PAF)-like lipids, prostaglandin E2 (PGE2) and catalase activity were determined as biochemical markers of oxidative stress and inflammation in muscle cells.

Results: UDCA significantly increased GB muscle cell contraction induced by all concentrations of CCK-8, ACh and KCl, and reduced the plasma membrane cholesterol (mean (SD) 0.32 (0.16) vs 0.72 (0.5) μmol/mg of protein) compared with placebo. In GB muscle cells, UDCA treatment significantly decreased the levels of H2O2 (4.4 (1.9) vs 13.7 (5.3) μmol/mg of protein), lipid peroxidation (malondialdehyde levels 1.3 (0.4) vs 2.52 (0.7) nmol/100 mg of protein), PAF-like lipids (8.9 (4.9) vs 29.6 (7.1) pg/mg of protein) as well as the production of PGE2 (142 (47) vs 365 (125) pg/mg of protein) and catalase activity (14.5 (9.4) vs 35.8 (12.7) units/mg of protein) when compared with placebo.

Conclusion: These studies suggest that UDCA treatment improves GB muscle contractility by decreasing the cholesterol content in the plasma membrane of muscle cells, and the biochemical parameters of oxidative stress, thus explaining its possible therapeutic mechanisms in patients with symptoms of cholesterol GSs.

  • AC, acute cholecystitis
  • ACh, acetylcholine
  • BDL, bile duct ligation
  • CCK, cholecystokinin
  • EIA, enzyme immunoassay
  • GB, gallbladder
  • GS, gallstone
  • KCl, potassium chloride
  • PAF, platelet-activating factor
  • PGE2, prostaglandin E2
  • ROS, reactive oxygen species
  • SPA, scintillation proximity assay
  • TCDC, taurochenodeoxycholic acid
  • UDCA, ursodeoxycholic acid

Statistics from Altmetric.com

Footnotes

  • Published Online First 21 December 2006

  • Funding: This study was partially supported by NIH grant RO1-DK27389-19 and was carried out in accordance with the Declaration of Helsinki.

  • Competing interests: None.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Digest
    Robin Spiller Emad El-Omar